DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Invasive Fungal Infections (IFIs) Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Invasive Fungal Infections Epidemiology, IFIs Market Size, Invasive Fungal Infections Market Forecast, current treatment landscape, IFIs Clinical Trials, Invasive Fungal Infections Pipeline, and emerging antifungal therapies across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan (7MM).
Key Takeaways from the Invasive Fungal Infections Market
The Invasive Fungal Infections Market Size across the 7MM is expected to witness considerable growth by 2036, supported by increasing disease incidence, expanding treatment eligibility, rising antifungal drug utilization, and the anticipated approval of several novel broad-spectrum antifungal agents.
The United States accounted for the largest Invasive Fungal Infections Treatment Market in 2025 and is expected to maintain its market leadership throughout the forecast period due to higher diagnosis rates, greater adoption of innovative antifungal therapies, favorable reimbursement policies, and increased awareness among healthcare professionals.
According to DelveInsight’s estimates, the US Invasive Fungal Infections Market was valued at nearly USD 390 million in 2025 and is projected to expand significantly through 2036, driven by increasing testing rates, rising therapy costs, and the expected launch of next-generation antifungal therapies.
The report estimates that approximately 112,000 incident cases of Invasive Fungal Infections occurred in the United States in 2025, with the patient population projected to increase steadily throughout the forecast period owing to the expanding population of immunocompromised individuals and critically ill patients.
Invasive Candidiasis and Invasive Aspergillosis together account for nearly 50% of the total IFI burden, making them the leading contributors to disease prevalence and antifungal drug utilization across the major markets.
Approximately 70% of diagnosed patients currently receive systemic antifungal therapy, highlighting a substantial treatment gap that continues to contribute to increased morbidity and mortality associated with invasive fungal infections.
The report highlights that nearly 90% of patients eventually develop resistance to first-line antifungal therapy, while around 30% subsequently develop resistance to second-line agents, emphasizing the urgent need for innovative antifungal drugs with novel mechanisms of action.
Leading Invasive Fungal Infections Companies, including Basilea Pharmaceutica, F2G Biotech GmbH, Shionogi, SCYNEXIS, Pulmocide, Matinas BioPharma, and others, are actively advancing innovative therapies that are expected to transform the IFIs Market over the coming decade.
The promising Invasive Fungal Infections Pipeline includes Fosmanogepix, Olorofim, SCY-247, MAT2203, and several additional investigational antifungal therapies designed to overcome resistance and improve outcomes in patients with difficult-to-treat fungal infections.
Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/invasive-fungal-infections-market
Key Factors Driving the Invasive Fungal Infections Market
Rising Incidence of Immunocompromised Patient Populations: The growing number of patients undergoing organ transplantation, hematopoietic stem cell transplantation, chemotherapy, immunosuppressive therapy, and intensive care treatment has significantly increased the incidence of Invasive Fungal Infections (IFIs). Patients with HIV/AIDS, diabetes, hematological malignancies, respiratory diseases, and prolonged corticosteroid use remain highly susceptible to life-threatening fungal infections, driving demand for advanced antifungal therapies.
Increasing Burden of Antifungal Resistance: The emergence of multidrug-resistant fungal pathogens, including Candida auris, azole-resistant Aspergillus, and resistant Candida species, has become a major clinical challenge. Resistance to first-line and second-line antifungal agents is increasing the need for novel antifungal drugs with innovative mechanisms of action capable of overcoming existing treatment limitations.
Growing Demand for Rapid Diagnosis and Targeted Therapy: Significant advances in molecular diagnostics, fungal biomarkers, PCR-based assays, next-generation sequencing, and improved surveillance are facilitating earlier diagnosis of Invasive Fungal Infections. Earlier identification allows physicians to initiate timely targeted antifungal therapy, improving clinical outcomes while reducing mortality and healthcare costs.
Strong Emerging Antifungal Pipeline: Pharmaceutical and biotechnology companies are actively developing next-generation broad-spectrum antifungal agents with improved efficacy, favorable safety profiles, enhanced tissue penetration, and activity against resistant fungal pathogens. These innovations are expected to reshape the Invasive Fungal Infections Treatment Market throughout the forecast period.
Invasive Fungal Infections Competitive Landscape
The Invasive Fungal Infections Pipeline is rapidly evolving with several promising therapies in mid- and late-stage clinical development. Companies including Basilea Pharmaceutica, Shionogi/F2G, SCYNEXIS, Matinas BioPharma, Pulmocide, and others are focused on developing innovative antifungal therapies to address the growing burden of resistant fungal infections.
Among the most promising pipeline candidates is Fosmanogepix, a first-in-class broad-spectrum antifungal agent being developed by Basilea Pharmaceutica. Fosmanogepix targets the fungal Gwt1 protein, a novel mechanism essential for fungal cell wall integrity, demonstrating potent activity against Candida, Candida auris, Aspergillus, Fusarium, Scedosporium, endemic fungi, and several rare molds. Its broad-spectrum activity positions it among the leading emerging therapies within the Invasive Fungal Infections Market.
Olorofim, being developed by Shionogi/F2G, is another highly anticipated antifungal therapy. It represents a first-in-class dihydroorotate dehydrogenase (DHODH) inhibitor with potent activity against difficult-to-treat molds, including invasive aspergillosis, and is expected to address significant unmet clinical needs in patients with refractory fungal infections.
SCY-247, developed by SCYNEXIS, is a second-generation triterpenoid antifungal demonstrating broad-spectrum antifungal activity, excellent tissue penetration, and promising activity against Candida auris and other resistant fungal pathogens. Meanwhile, MAT2203 from Matinas BioPharma is being developed as an innovative oral lipid nanocrystal formulation designed to improve amphotericin B delivery while reducing systemic toxicity.
The growing number of innovative therapies targeting novel fungal pathways, combined with increasing investment in infectious disease research, is expected to significantly strengthen the competitive landscape of the Invasive Fungal Infections Market over the next decade.
Discover more about therapies set to grab major Invasive Fungal Infections Market share @ Invasive Fungal Infections Treatment Landscape
Recent Developments in the Invasive Fungal Infections Market
In January 2026, SCYNEXIS announced that the US FDA granted Qualified Infectious Disease Product (QIDP) designation and Fast Track Designation (FTD) to SCY-247, further supporting its development for the treatment of invasive fungal infections.
In January 2026, SCYNEXIS presented new preclinical data on SCY-247 at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), highlighting its potent antifungal activity against resistant fungal pathogens.
In January 2026, Basilea Pharmaceutica announced continued strong commercial performance of CRESEMBA, with milestone payments triggered through its commercialization partnership with Pfizer following strong sales growth across the Asia-Pacific region.
In July 2025, Basilea Pharmaceutica received USD 39 million under its BARDA agreement to continue advancing Fosmanogepix, while ongoing Phase III clinical studies continue evaluating the therapy for candidemia, invasive candidiasis, and invasive mold infections.
What are Invasive Fungal Infections?
Invasive Fungal Infections (IFIs) are severe, life-threatening fungal diseases that occur when pathogenic fungi invade deep tissues, the bloodstream, or vital organs, predominantly affecting immunocompromised individuals. Patients undergoing organ transplantation, chemotherapy, immunosuppressive therapy, intensive care, or those with HIV/AIDS, diabetes, hematological malignancies, or chronic respiratory diseases are at particularly high risk. Major forms of IFIs include Invasive Candidiasis, Invasive Aspergillosis, Mucormycosis, Cryptococcosis, Histoplasmosis, Blastomycosis, Coccidioidomycosis, and other rare mold infections. Despite the availability of antifungal agents such as azoles, echinocandins, polyenes, and flucytosine, delayed diagnosis, limited therapeutic options, increasing antifungal resistance, and high mortality rates continue to present significant clinical challenges. The emergence of novel broad-spectrum antifungal therapies, improved molecular diagnostics, and innovative precision treatment approaches is expected to transform the future Invasive Fungal Infections Treatment Market, improving survival and clinical outcomes for patients worldwide.
Invasive Fungal Infections Epidemiology Segmentation
The Invasive Fungal Infections epidemiology section provides insights into the historical and current Invasive Fungal Infections patient pool and forecasted trends for the leading markets. The Invasive Fungal Infections market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Total Incident Cases of Invasive Fungal Infections
Type-specific Incident Cases of Invasive Fungal Infections
Pathogen-specific Incident Cases of Invasive Fungal Infections
Severity-specific Incident Cases of Invasive Fungal Infections
Age-specific Incident Cases of Invasive Fungal Infections
Scope of the Invasive Fungal Infections Market Report
Therapeutic Assessment: Current marketed and emerging Invasive Fungal Infections Therapies
Invasive Fungal Infections Market Dynamics: Key Market Forecast Assumptions of Emerging Invasive Fungal Infections Drugs and Market Outlook
Key Companies: Basilea Pharmaceutica, F2G Biotech GmbH, Shionogi, SCYNEXIS, Pulmocide, Matinas BioPharma, Cidara Therapeutics, Pfizer, and others
Key Therapies: Fosmanogepix, Olorofim, SCY-247, MAT2203, CRESEMBA, REZZAYO, ERAXIS, NOXAFIL, TOLSURA, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
Unmet Needs, KOL’s Views, Analyst’s Views, Invasive Fungal Infections Market Access and Reimbursement
To know more about Invasive Fungal Infections companies working in the treatment market, visit @ Invasive Fungal Infections Clinical Trials and Therapeutic Assessment
Table of Contents
Invasive Fungal Infections Market Report Introduction
Executive Summary for Invasive Fungal Infections
SWOT Analysis of Invasive Fungal Infections
Invasive Fungal Infections Patient Share (%) Overview at a Glance
Invasive Fungal Infections Market Overview at a Glance
Invasive Fungal Infections Background and Overview
Invasive Fungal Infections Epidemiology and Patient Population
Country-Specific Patient Population of Invasive Fungal Infections
Invasive Fungal Infections Current Treatment and Medical Practices
Invasive Fungal Infections Unmet Needs
Invasive Fungal Infections Emerging Therapies
Invasive Fungal Infections Market Outlook
Country-Wise Invasive Fungal Infections Market Analysis (2022–2036)
Invasive Fungal Infections Market Access and Reimbursement of Therapies
Invasive Fungal Infections Market Drivers
Invasive Fungal Infections Market Barriers
Invasive Fungal Infections Appendix
Invasive Fungal Infections Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
